News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,830 Results
Type
Article (2570)
Company Profile (3)
Press Release (11257)
Section
Business (5178)
Career Advice (72)
Deals (874)
Drug Delivery (8)
Drug Development (2322)
Employer Resources (6)
FDA (405)
Job Trends (698)
News (8631)
Policy (974)
Tag
Academia (40)
Allergies (4)
Alliances (1327)
ALS (6)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (6)
Approvals (405)
Artificial intelligence (7)
Autoimmune disease (4)
Bankruptcy (6)
Best Places to Work (482)
Cancer (38)
Career advice (53)
Cell therapy (8)
Clinical research (1850)
Collaboration (20)
COVID-19 (202)
C-suite (13)
Data (42)
Diabetes (12)
Diagnostics (60)
Drug discovery (5)
Drug pricing (8)
Earnings (1250)
Editorial (4)
Employer resources (5)
Events (1008)
Executive appointments (28)
FDA (426)
Funding (23)
Gene therapy (7)
GLP-1 (70)
Government (217)
Healthcare (285)
Immunology and inflammation (13)
Infectious disease (211)
Inflammatory bowel disease (6)
Interviews (12)
IPO (205)
Job creations (241)
Job search strategy (53)
Layoffs (40)
Legal (237)
Lung cancer (6)
Lymphoma (5)
Manufacturing (7)
Medical device (53)
Medtech (53)
Mergers & acquisitions (671)
Metabolic disorders (23)
Multiple sclerosis (12)
Neurodegenerative disease (6)
Neuroscience (41)
NextGen: Class of 2025 (158)
Non-profit (65)
Northern California (103)
Obesity (9)
Opinion (27)
People (2230)
Phase I (507)
Phase II (697)
Phase III (883)
Pipeline (34)
Podcasts (9)
Policy (4)
Postmarket research (162)
Preclinical (151)
Radiopharmaceuticals (9)
Rare diseases (19)
Real estate (160)
Regulatory (621)
Research institute (43)
Resumes & cover letters (12)
RSV (5)
Series A (3)
Series B (5)
Southern California (29)
Startups (134)
The Weekly (9)
United States (293)
Vaccines (57)
Venture capitalists (3)
Weight loss (9)
Date
Last 7 days (16)
Last 30 days (76)
Last 365 days (769)
2025 (129)
2024 (753)
2023 (759)
2022 (1570)
2021 (1380)
2020 (1158)
2019 (777)
2018 (636)
2017 (830)
2016 (748)
2015 (896)
2014 (564)
2013 (494)
2012 (502)
2011 (503)
2010 (466)
Location
Africa (55)
Asia (773)
Australia (93)
California (136)
Canada (16)
China (26)
Europe (4197)
Florida (6)
Maryland (7)
Massachusetts (43)
New Jersey (14)
New York (60)
North Carolina (4)
Northern California (103)
Pennsylvania (14)
South America (60)
Southern California (29)
13,830 Results for "sanofi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
January 30, 2025
·
2 min read
·
Dan Samorodnitsky
Legal
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that determine pricing and rebates for the drug.
February 7, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered
E. coli
Vaccine
Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive
E. coli
disease versus placebo.
February 13, 2025
·
2 min read
·
Tristan Manalac
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.
October 17, 2024
·
2 min read
·
Tristan Manalac
Healthcare
As Sanofi Preps Consumer Healthcare Sale, Here’s a Look Back at Similar High-Profile Deals
Sanofi looks to follow a deep history of Big Pharma offloading their consumer healthcare businesses.
October 16, 2024
·
6 min read
·
Annalee Armstrong
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Deals
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.
October 21, 2024
·
2 min read
·
Annalee Armstrong
Multiple sclerosis
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage win in relapsing multiple sclerosis, demonstrating near-total elimination of disease activity.
September 4, 2024
·
2 min read
·
Tristan Manalac
Approvals
Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma, Tees Up Competition With J&J
With Friday’s approval, Sanofi’s anti-CD38 antibody Sarclisa will go head-to-head with the first such therapy for multiple myeloma, Johnson & Johnson’s Darzalex, which raked in nearly $10 billion last year.
September 23, 2024
·
2 min read
·
Tristan Manalac
1 of 1,383
Next
